ST. PETERSBURG, FL--(Marketwire - Dec 4, 2012) - Lenstec, Inc. -- a manufacturer of technologically-advanced implantable lenses for correcting vision -- has launched U.S. sales of its new Softec HD Oval (HDO) Intraocular Lens, which was cleared by the U.S. Food and Drug Administration in June as the first oval, one-piece foldable IOL for treating cataract patients.
The HDO's unique oval center measures 5.75 mm x 6.5 mm and provides almost 30 percent more coverage across the visual plane compared to standard IOLs. It is also the largest, single-piece foldable IOL available.
The HDO's larger optic may reduce the likelihood of adverse effects commonly associated with cataract removal surgery. A study by renowned ophthalmic surgeon Jack Holladay, MD published in the Journal of Cataract and Refractive Surgery theorized that negative dysphotopsia (i.e., unwanted shadows or reflection caused by oblique light entering the eye and "bouncing" off an IOL's edges) may be reduced with use of a one-piece IOL placed horizontally (1). A prior study by Robert Osher, M.D. reported that negative dysphotopsia affected 15.2 percent of cataract patients examined at one day post-op (2).
Similarly, Dale Pilkinton, MD of Pilkinton Eye Center (Nashville, TN) has said problems such as negative dysphotopsia are, "simply a case of the wrong size or shape lens with inadequate coverage of the optical axis and pupil. Negative Dysphotopsia does not go away. Surgeons and their patients are merely forced to live with it."
"We expect the HDO's unique IOL design will help surgeons make the best decisions for their patients," said Lenstec Vice President George Wiseman. "We are delighted the Softec HDO is now readily available to cataract surgeons in the U.S. and internationally."
The Softec HDO is part of Lenstec's Precision Series™ line of premium IOLs. Based on the company's proprietary lens manufacturing technology, these lenses are designed to deliver unmatched predictability and precision in cataract surgery by reducing the variability (i.e., tolerance or margin of error) inherent in any manufactured lens.
"We are very excited with the rapid early adaption of this IOL in the market, with nearly 1,000 Softec HDO implants by approximately 50 ophthalmologists in just six weeks," said Lenstec CEO John Clough. "The very positive comments from surgeons and demand for this oval IOL are impressive."
In addition to reducing variability, Lenstec's manufacturing process makes it possible to produce the Softec HDO in a range of 5.0 to 30.0 diopters, and in non-overlapping quarter diopter (0.25 D) increments from 15.0 to 25.0 diopters.
More information about the Softec HDO and Lenstec's Precision Series IOLs is available at http://www.lenstec.com
Lenstec is a leading designer and manufacturer of intraocular lenses (IOLs) to treat patients with a range of vision disorders. Founded in 1992, the company is dedicated to advancing possibilities for ophthalmic professionals and their patients worldwide. More information about Lenstec is available at www.lenstec.com.
(1) Holladay, J et al. Negative dysphotopsia: The enigmatic penumbra. J Cataract Refract Surg 2012; 38:1256-1270.
(2) Osher RH. Negative dysphotopsia: long-term study and possible explanation for transient symptoms. J Cataract Refract Surg 2008; 34:1699-1707.